Effect of tranilast in early-stage diabetic nephropathy

Soma, Jun; Satô, Kôzô; Saito, H; Tsuchiya, Y.

doi:10.1093/ndt/gfl325

Cited by 44 publications

(30 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10,11 Furthermore, tranilast is potentially useful for suppressing the progression of early diabetic nephropathy. 12 Tranilast has several other antifibrotic effects, including some exerted through the suppression of NFkB. 13 These include attenuating the CTGF-induced extracellular matrix accumulation in renal cells, 8 inhibiting the production of PDGF and IL-1 by monocytes and macrophages and inhibiting the production of MCP-1 by rat mesangial cells.…”

Section: Discussionmentioning

confidence: 99%

Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD

Ogawa

Doğru

Uchino

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

Fibrosis and excessive extracellular matrix production are characteristic features of lacrimal gland chronic GVHD (cGVHD). Tranilast (n-[3,4-anthoranilic acid]), used for fibrotic skin disease, inhibits transforming growth factorb-induced matrix production. We conducted a nonrandomized study comparing 8 patients (five men, three women; median age, 47 years) given topical tranilast with 10 patients (three men, seven women; median age, 37 years) receiving therapy with topical artificial tears, sodium hyaluronate and vitamin A for mild ocular cGVHD. The tranilast group instilled topical tranilast and artificial tears q.i.d., beginning the day of dry eye diagnosis. The ocular surface and tear dynamics of each patient were evaluated before hematopoietic stem cell transplant, at the onset of dry eye and after 3 months of treatment. At 3 months, the scores of the Rose Bengal test and Schirmer test with nasal stimulation had significantly improved in the tranilast group compared with that in the control group (Po0.05). Furthermore, although five control patients (50%) developed severe dry eye within the treatment period, only one tranilast-treated patient (12.5%) did; the rest still had mild dry eye (Po0.05). These results suggest the hypothesis that topical tranilast may effectively retard the progression of mild dry eye associated with cGVHD.

show abstract

Section: Discussionmentioning

confidence: 99%

Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD

Ogawa

Doğru

Uchino

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…[90] DRUGS-Pirfenidone [133] , Tranilast [134,135] , fresolimumab. [136,137] TGFβ BLOCKERS-have been tested in animal models but human study yet to be tested [138,139] Fresolimumab, tranilast-reduces proteinuria. Pirfenidone -pilot study shows beneficial renal effect but were halted due to adverse effect.…”

Section: ) Albuminuriamentioning

confidence: 99%

Drugs for Diabetic Nephropathy- Full Review

Soni¹

2017

WJPPS

View full text Add to dashboard Cite

show abstract

“…Changes in practice patterns leading to the decrease in early starts were influenced by well designed, patientoriented research informing conversations with patients around the timing of and need for renal replacement therapy. [9][10][11][12][13][14][15][16][17][18][19] The knowledge gained from these studies and others about the pros and cons of therapy options, including maximum conservative management, should be incorporated into patient-centered, age-relevant decision aids, a tool that is successful in helping patients understand the effect of various options on their healthcare goals and personal priorities. 20,21 Unfortunately, many elderly patients do not decide whether to pursue renal replacement therapy while they are in calm, controlled preemptive settings.…”

Section: Disclosuresmentioning

confidence: 99%

“…It is used as an antifibrotic agent in Southeast Asia for the treatment of keloid formation. In addition, the drug has been evaluated experimentally 8 as well as clinically in diabetic nephropathy, 9 although clinical use was confined to only a few patients. Pentoxifylline is a methylxanthine phosphodiesterase inhibitor that has been evaluated in more than 20 studies, mostly in patients with diabetic nephropathy.…”

mentioning

confidence: 99%